# Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia

> **NCT00099996** · PHASE3 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 3 (—)

## Conditions studied

- Heart Diseases
- Metabolism, Inborn Errors

## Interventions

- **DRUG:** SCH-58235
- **DRUG:** Ezetimibe

## Key facts

- **NCT ID:** NCT00099996
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-12
- **Primary completion:** —
- **Final completion:** 2005-12
- **Target enrollment:** 3 (—)
- **Last updated:** 2008-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00099996

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00099996, "Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00099996. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*